We are live on ! Find out more

Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
PHAT icon
201
Phathom Pharmaceuticals
PHAT
$769M
$769M $9.50 4.97%
ASMB icon
202
Assembly Biosciences
ASMB
$745M
$745M $36.60 1.3%
VSTM icon
203
Verastem
VSTM
$743M
$743M $8.20 2.76%
ZVRA icon
204
Zevra Therapeutics
ZVRA
$736M
$736M $12.40 1.12%
GYRE icon
205
Gyre Therapeutics
GYRE
$727M
$727M $6.86 6.52%
BBOT
206
BridgeBio Oncology
BBOT
$720M
$720M $8.98 0.9%
STTK icon
207
Shattuck Labs
STTK
$681M
$681M $6.79 2.44%
ALLO icon
208
Allogene Therapeutics
ALLO
$681M
$681M $1.97 0.51%
SGMT icon
209
Sagimet Biosciences
SGMT
$680M
$680M $10.94 0.18%
OCS icon
210
Oculis Holding
OCS
$676M
$676M $12.17 0%
PRME icon
211
Prime Medicine
PRME
$671M
$671M $3.70 0.27%
MDXG icon
212
MiMedx Group
MDXG
$666M
$666M $4.57 3.16%
ALT icon
213
Altimmune
ALT
$665M
$665M $3.42 5.88%
CRMD icon
214
CorMedix
CRMD
$657M
$657M $8.43 0.47%
VALN
215
Valneva
VALN
$653M
$653M $6.89 2.41%
BLSM
216
BlossomHill Therapeutics
BLSM
$640M
$640M $22.01 9.94%
DRUG
217
Bright Minds Biosciences
DRUG
$639M
$639M $65.16 4.2%
MPLT
218
MapLight Therapeutics
MPLT
$639M
$639M $13.77 4.79%
OABI icon
219
OmniAb
OABI
$630M
$630M $4.33 8.84%
CTNM
220
Contineum Therapeutics
CTNM
$628M
$628M $16.70 4.95%
ARVN icon
221
Arvinas
ARVN
$614M
$614M $9.39 0.86%
TECX
222
Tectonic Therapeutic
TECX
$601M
$601M $30.75 2.77%
ZURA icon
223
Zura Bio
ZURA
$597M
$597M $6.23 5.95%
AUTL
224
Autolus Therapeutics
AUTL
$596M
$596M $2.24 2.18%
RGNX icon
225
Regenxbio
RGNX
$590M
$590M $8.94 2.83%
7 8
9
10 11

Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 568 Biotechnology industry stocks tracked by Wall St. Rank, worth a combined $1.35T.

The largest by market cap are Vertex Pharmaceuticals (VRTX) at $138B, Regeneron Pharmaceuticals (REGN) at $85.2B and argenx (ARGX) at $64.6B.

Among institutional investors, Revolution Medicines (RVMD) drew the most net new fund positions in Q2 2026: 243 funds opened new positions, taking total fund holders up 177 (34%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.